Table 1. Demographics of the major explanatory variables in kidney transplantation recipients (n=519).
| Variables | Severe pneumonia | P value | |
|---|---|---|---|
| No (n=476) | Yes (n=43) | ||
| Preoperative variables | |||
| Age | 42.84±11.24 | 50.07±10.60 | <0.001 |
| Sex | 0.388 | ||
| Female | 143 | 10 | |
| Male | 333 | 33 | |
| Blood type | 0.928 | ||
| A | 104 | 8 | |
| B | 125 | 11 | |
| AB | 40 | 3 | |
| O | 207 | 21 | |
| Diabetes | 0.022 | ||
| Yes | 50 | 10 | |
| No | 426 | 33 | |
| HBsAg | 0.037 | ||
| Positive | 47 | 9 | |
| Negative | 429 | 34 | |
| Dialysis type | 0.072 | ||
| No dialysis | 50 | 1 | |
| Hemodialysis | 327 | 28 | |
| Peritoneal dialysis | 99 | 14 | |
| Dialysis duration | 0.12 | ||
| No dialysis | 50 | 2 | |
| ≤1 year | 255 | 19 | |
| >1 year | 171 | 22 | |
| Preoperative albumin | 43.8 (40.5–46.8) | 41.5 (36.3–45.5) | 0.011 |
| Preoperative immunoglobulin | 28.2 (24.9–31.35) | 29.9 (27.0–33.5) | 0.01 |
| Preoperative pulmonary radioscopic inflammatory lesion (pulmonary edema excluded) | <0.001 | ||
| Yes | 41 | 17 | |
| No | 435 | 26 | |
| Donor age | 40.96±14.45 | 46.86±12.13 | 0.005 |
| Intra and postoperative variables | |||
| Surgery time (hours) | 3.33 (2.94–3.92) | 3.70 (3.12–4.27) | 0.027 |
| Reoperation | <0.001 | ||
| No | 466 | 36 | |
| Yes | 10 | 7 | |
| Induction | >0.999 | ||
| T-cell depletion | 423 | 39 | |
| Non-depletion | 53 | 4 | |
| rATG dose (bolus) | 6 (4–8) | 6 (6–8) | 0.056 |
| Anti-fungi drugs | 0.026 | ||
| Caspofungin | 209 | 25 | |
| Micafungin | 266 | 17 | |
| Other | 1 | 1 | |
| Delayed graft function | 0.005 | ||
| Yes | 40 | 10 | |
| No | 436 | 33 | |
Differences test in continuous variables were analyzed using the Wilcoxon rank-sum test; differences in categorical variables were analyzed using Fisher’s exact test. WBC, white blood cell; BUN, blood urea nitrogen; CVD, cardiac vascular disease; HDL, high density lipoprotein cholesterol; LDL, low-density lipoprotein; IVIg, intravenous immunoglobulin; rATG dose, rabbit anti-human thymocyte globulin (Thymoglobulin® 25 mg/bolus), we also used ATG-F: anti-human T lymphocyte rabbit immunoglobulin (Grafalon®, 100 mg converted to rATG in two boluses) and ALG: porcine anti-human lymphocyte immunoglobulin (250 mg/bolus, converted to rATG in one bolus).